nonsquamous non-small cell lung cancer

ESMO: In PD-1 battle GSK waged on Merck, Jemperli appears to show survival edge over Keytruda in lung cancer
Fierce Pharma
Fri, 10/20/23 - 11:47 am
Merck
GSK
Keytruda
Jemperli
ESMO
nonsquamous non-small cell lung cancer